Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AllerT1
- Development stage
- Preclinical
- Modality
- Peptides
- Administration
- Intradermal
01
Overview
AllerT1 is a synthetic peptide referenced in clinical trials for skin prick testing in subjects allergic to birch. It appears to be used as an investigational agent for allergy diagnostics or research, specifically targeting birch pollen allergy. The mechanism of action is not fully described in available sources, but it is likely designed to mimic allergenic epitopes from birch pollen for diagnostic or desensitization purposes[3]. There is no evidence of therapeutic use beyond research and diagnostic applications.
- Other names
- synthetic peptide T1AllerT1AllerT-1AllerT 1
02
Targets
HLA-DR (Human leukocyte antigen DR)γδ TCR (T-cell receptor)
Beyond the preview
Go deeper on AllerT1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AllerT1.